Literature DB >> 21850599

Long-term outcomes of extended proximal gastrectomy for oesophagogastric junctional tumours.

Omar Khan1, Steven Goh, Ben Byrne, Shaw Somers, Stuart Mercer, Simon Toh.   

Abstract

BACKGROUND: There is no consensus on the optimum approach for resection of oesophagogastric junctional (OGJ) tumours. We prospectively evaluated the efficacy of transabdominal radical extended proximal gastrectomy with oesophagogastric anastomosis (EPGOG) for selected tumours of the OGJ.
METHODS: Between 1998 and 2007, 66 selected consecutive patients with tumours of the OGJ underwent successful EPGOG. Selection was limited to tumours where the maximal proximal extent was 36 cm ab oral. Pre-, peri-, and postoperative outcomes together with long-term survival data for these patients were prospectively collected.
RESULTS: Median theatre time was 242 min (range = 120-480), with a median blood loss of 300 ml (range = 50-1720). Eighty-nine percent of patients were extubated in theatre; major complications occurred in 9 (14%) patients, with an overall in-hospital mortality rate of 8%. Thirty-five (53%) patients had nodal disease and the median lymph node yield was 13 (range = 4-36), with an R0 resection rate of 80%. In terms of long-term outcomes, the 2- and 5-year actuarial survival rates were 54 ± 6% and 41 ± 6%.
CONCLUSION: Extended radical proximal gastrectomy with oesophagogastric anastomosis for selected junctional tumours is a feasible technique which does not compromise oncological principles as evidenced by an excellent long-term survival rate.

Entities:  

Mesh:

Year:  2011        PMID: 21850599     DOI: 10.1007/s00268-011-1235-z

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  22 in total

1.  Transhiatal approach to total gastrectomy for adenocarcinoma of the gastric cardia.

Authors:  J Wayman; S M Dresner; S A Raimes; S M Griffin
Journal:  Br J Surg       Date:  1999-04       Impact factor: 6.939

2.  Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis.

Authors:  J B Hulscher; J G Tijssen; H Obertop; J J van Lanschot
Journal:  Ann Thorac Surg       Date:  2001-07       Impact factor: 4.330

Review 3.  Is an involved circumferential resection margin following oesphagectomy for cancer an important prognostic indicator?

Authors:  Omar A Khan; David Cruttenden-Wood; Simon K Toh
Journal:  Interact Cardiovasc Thorac Surg       Date:  2010-08-24

4.  Preoperative prediction of the risk of pulmonary complications after esophagectomy for cancer.

Authors:  Mark K Ferguson; Amy E Durkin
Journal:  J Thorac Cardiovasc Surg       Date:  2002-04       Impact factor: 5.209

5.  Three-field lymphadenectomy and pattern of lymph node spread in T3 adenocarcinoma of the distal esophagus and the gastro-esophageal junction.

Authors:  C van de Ven; P De Leyn; W Coosemans; D Van Raemdonck; T Lerut
Journal:  Eur J Cardiothorac Surg       Date:  1999-06       Impact factor: 4.191

6.  Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus.

Authors:  Jan B F Hulscher; Johanna W van Sandick; Angela G E M de Boer; Bas P L Wijnhoven; Jan G P Tijssen; Paul Fockens; Peep F M Stalmeier; Fiebo J W ten Kate; Herman van Dekken; Huug Obertop; Hugo W Tilanus; J Jan B van Lanschot
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

7.  Optimum lymphadenectomy for esophageal cancer.

Authors:  Nabil P Rizk; Hemant Ishwaran; Thomas W Rice; Long-Qi Chen; Paul H Schipper; Kenneth A Kesler; Simon Law; Toni E M R Lerut; Carolyn E Reed; Jarmo A Salo; Walter J Scott; Wayne L Hofstetter; Thomas J Watson; Mark S Allen; Valerie W Rusch; Eugene H Blackstone
Journal:  Ann Surg       Date:  2010-01       Impact factor: 12.969

8.  Outcomes following oesophagectomy in patients with oesophageal cancer: a secondary analysis of the ICNARC Case Mix Programme Database.

Authors:  Daniel P Park; Catherine A Welch; David A Harrison; Thomas R Palser; David A Cromwell; Fang Gao; Derek Alderson; Katherine M Rowan; Gavin D Perkins
Journal:  Crit Care       Date:  2009       Impact factor: 9.097

9.  Esophagectomy without thoracotomy: 25 years of experience over 750 patients.

Authors:  Panagiotis Yannopoulos; Panagiotis Theodoridis; Konstantinos Manes
Journal:  Langenbecks Arch Surg       Date:  2009-04-07       Impact factor: 3.445

10.  Prognostic significance of circumferential resection margin involvement following oesophagectomy for cancer.

Authors:  O A Khan; J J Fitzgerald; I Soomro; F D Beggs; W E Morgan; J P Duffy
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

View more
  4 in total

Review 1.  Quality of life: A critical outcome for all surgical treatments of gastric cancer.

Authors:  Michael D McCall; Peter J Graham; Oliver F Bathe
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

2.  Total vs proximal gastrectomy for adenocarcinoma of the upper third of the stomach: a propensity-score-matched analysis of a multicenter western experience (On behalf of the Italian Research Group for Gastric Cancer-GIRCG).

Authors:  Fausto Rosa; Giuseppe Quero; Claudio Fiorillo; Massimiliano Bissolati; Chiara Cipollari; Stefano Rausei; Damiano Chiari; Laura Ruspi; Giovanni de Manzoni; Guido Costamagna; Giovanni Battista Doglietto; Sergio Alfieri
Journal:  Gastric Cancer       Date:  2018-02-08       Impact factor: 7.370

3.  Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis.

Authors:  Jonathan Cools-Lartigue; Jonathan Spicer; Braedon McDonald; Stephen Gowing; Simon Chow; Betty Giannias; France Bourdeau; Paul Kubes; Lorenzo Ferri
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

Review 4.  Toll-like receptors: exploring their potential connection with post-operative infectious complications and cancer recurrence.

Authors:  S D Gowing; J J Cool-Lartigue; J D Spicer; A J E Seely; L E Ferri
Journal:  Clin Exp Metastasis       Date:  2020-01-23       Impact factor: 5.150

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.